INVITAE CORP. DL-,0001 WKN: A14NKG ISIN: US46185L1035 Kürzel: NVTA Forum: Aktien Thema: Hauptdiskussion

Solange 3,03 nicht auf Tagesbasis überschritten werden, ist der Abwärtstrend weiter intakt.

🚀 🚀 🚀 🚀 🚀 🚀 🚀

leicht verdientes geld. heut abend stehts wieder unter 2,70 ;)

2,95 nochmal short nachgelegt :)

Krasser Anstieg

2,80 neuer Short ;)

Sieht gut aus 👍

uiiii, sehr schöne neue Shorteinstiege :)

Hier passiert nix, wahrscheinlich sehr schlechte Zahlen

dann solltest mal die Brille putzen :D

Wo denn? Ich sehe nur eine Richtung 🚀

Auf gehts :) der Weg zur 1,80€ ist geebnet.

https://www.fool.com/earnings/call-transcripts/2022/11/08/invitae-nvta-q3-2022-earnings-call-transcript/

Alles sehr positiv mal sehen was kommt, die setzen alles um und nach plan 👍

Voila

Third Quarter 2022 Highlights Generated revenue of $133.5 million, a 16.7% increase compared to $114.4 million in the third quarter of 2021. GAAP gross profit was $16.6 million, and non-GAAP gross profit was $61.2 million. GAAP gross margin was 12.4%. Non-GAAP gross margin was 45.9% as compared with 40.1% in the second quarter of 2022 and 35.6% in the third quarter of 2021. Cash, cash equivalents, restricted cash and marketable securities were $596.0 million as of September 30, 2022, compared to $736.8 million as of June 30, 2022. Cash burn was $151.5 million, which excludes a $9.7 million inflow from sales under our ATM facility. Our cash burn was $108.3 million after adjustments for outflows of $29.1 million related to realignment and $14.1 million related to contingent consideration held for past M&A transactions. Total active healthcare provider accounts totaled 20,831 as of September 30, an increase of approximately 20% year-over-year. Active pharmaceutical and commercial partnerships grew to 234, an increase of approximately 38% year-over-year, due to revenue growth from lab services, data services to pharmaceutical, health systems and other partners. Revenue per patient was $505, an increase of approximately 8% from $468 in the third quarter of 2021. Total patient population as of September 30 is more than 3.3 million with over 62% available for data sharing.